Skip to main content

Prostate.

49 Phase 2 studies recruiting right now, most recently updated first.

Open the Phase 2 page · a list of only those studies

Triangle is made by Triangle Health, Inc.

Prostate49 studies

PSMA PET-Positive Castration-Resistant Prostate CancerФаза 2NCT06549465

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

In-111 rosopatamab tetraxetan, 45 kBq/kg Ac-225 rosopatamab tetraxetan, 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 60 kBq/kg Ac-225 rosopatamab tetraxetan

Convergent TherapeuticsOpen the brief

Clinical trials: Phase 1 and Phase 2, explained